All patients
age >= 55 yr age >= 65 yr critical disease omicron variant BA.1 (B.1.1.529) solid organ transplant recipients subjects at risk
Immunostimulants drugs in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
0.61 [0.41 ; 0.92 ] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1 0% 1,197 NA not evaluable deathsdetailed results Libster, 2020 0.50 [0.09; 2.71]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
0.61 [0.41 ; 0.90 ] Libster, 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 2 0% 1,357 moderate not evaluable clinical deteriorationdetailed results Libster, 2020 0.52 [0.29; 0.94]
0.52 [0.29 ; 0.94 ] Libster, 2020 1 0% 160 NA not evaluable death or ventilationdetailed results Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
0.66 [0.46 ; 0.94 ] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1 0% 1,197 NA not evaluable hospital dischargedetailed results Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
1.48 [1.05 ; 2.09 ] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1 0% 1,197 NA not evaluable hospitalizationdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
1.00 [0.14 ; 7.34 ] Jagannathan, 2020 1 0% 120 NA not evaluable viral clearance detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
0.81 [0.56 ; 1.18 ] Jagannathan, 2020 1 0% 120 NA not evaluable viral clearance (time to event analysis only)detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
0.81 [0.56 ; 1.18 ] Jagannathan, 2020 1 0% 120 NA not evaluable ICU admissiondetailed results Libster, 2020 0.33 [0.07; 1.58]
0.33 [0.07 ; 1.58 ] Libster, 2020 1 0% 160 NA not evaluable serious adverse eventsdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
1.00 [0.14 ; 7.34 ] Jagannathan, 2020 1 0% 120 NA not evaluable adverse eventsdetailed results Jagannathan, 2020 1.33 [0.63; 2.78]
1.33 [0.63 ; 2.78 ] Jagannathan, 2020 1 0% 120 NA not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-27 14:33 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 90
- treatments: 597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567
- roots T: 290
